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Introduction: COPD is a leading cause of death worldwide; however, prevalence estimates
have varied considerably in previous studies. This study aimed to determine the prevalence
and severity of COPD in Copenhagen using data from the 4th examination of The Copenhagen
City Heart Study, to investigate the relationship between tobacco consumption and COPD, and
to characterize the subjects with COPD with regard to BMI, dyspnoea, treatment with respira-
tory medication and co-morbidities.
Methods: 6236 people participated. All non-asthmatic participants aged 35 years or older with
adequate lung function data were included for the final prevalence analyses (nZ 5,299). COPD
staging was done according to the GOLD criteria.
Results: The overall prevalence of COPD was 17.4%. The prevalence increased with age and
was higher among males. 6.2% had mild COPD, 9.2% had moderate COPD, and 2.0% had severe
or very severe COPD. Tobacco consumption was closely linked to both prevalence and disease
severity. Subjects with COPD had lower mean Body Mass Index (BMI) and more frequently
a BMI < 21 kg/m2. Dyspnoea was correlated to lung function but a substantial number of partic-
ipants with severe COPD experienced no dyspnoea. Only a minority of subjects with COPD
received pulmonary medication.
COPD was associated with cardiovascular disease and cancer.
Conclusion: The prevalence of COPD in Denmark is among the highest in the world. It is closely
correlated to smoking and age. It is accompanied by substantial co-morbidity and it is grossly
under treated.
ª 2010 Elsevier Ltd. All rights reserved., 4130 Viby Sj, Denmark. Tel.: þ45 46195913.
il.dk (P. Fabricius).
0 Elsevier Ltd. All rights reserved.
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COPD is characterized by chronic inflammation of the
airways gradually leading to airflow limitation. Smoking is
by far the leading cause of COPD in Western countries and
recent findings suggest that at least 40% of all smokers will
develop any COPD and 25% clinically significant COPD.1 In
the early stages of the disease symptoms are widely
neglected often delaying diagnosis until the disease has
progressed to an advanced stage.
Every year COPD is responsible for millions of deaths
worldwide and is the cause of morbidity to an even greater
extent. Smoking prevalence is slowly declining in the
Western world but continues to rise elsewhere and it is
estimated that the global impact of COPD will increase
further in the years to come.2e4
Estimates of prevalence from industrialized countries
range widely reflecting both true differences as well as
differences in the definition of COPD and the diagnostic tools
used in the surveys. Most studies find a prevalence of 10e15%
in the population above 35e40 years of age.5e16 The
CopenhagenCity Heart Study is one of the largest and longest
running cohort studies focusing on pulmonary aspects. In this
paper we used the latest data to give an updated estimate of
prevalence of COPD in Copenhagen along with a determina-
tion of disease severity. To facilitate comparison with other
studies the prevalence and severity of COPD were stated in
various age groups and the participants were characterized
by smoking history. In addition, we wanted to describe the
participants in terms of Body Mass Index (BMI), co-morbid-
ities, dyspnoea and treatment with respiratory medications
as these variables have been shown to be of prognostic
importance.17
Methods
All subjects included in this study participated in the
Copenhagen City Heart Study, a prospective epidemiologic
study initiated in 1976e1978. A sample of 19,698 subjects
aged 20 years or older was selected at random, after age
stratification in 5-year age groups, from residents of
Copenhagen. 14,223 subjects participated in the initial
survey at Copenhagen University Hospital. They were all
reinvited to participate in later surveys along with addi-
tional subjects in the youngest age group. A total of 6237
attended the fourth survey (response rate 50%). The
participants filled out a self-administered questionnaire,
which was checked together with an investigator to ensure
that the responses were accurate.
At this survey, forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) were measured with a dry wedge
spirometer (Vitalograph, Maidenhead, UK), calibrated daily
with a 1 L syringe. At each examination three sets of values
were obtained and as a criterion for correct performance of
procedure at least twomeasurements differingby less than5%
had to be produced. Only pre-bronchodilator measurements
were available. The results from asymptomatic never-
smokerswere used to calculate prediction values (FEV1%pred)
for FEV1 in the study sample. The prediction equations were:
Men: FEV1 (ml) Z 3763e35.2 * age (years) þ 52.9 *
height (cm).Women: FEV1 (ml) Z 1431e28.5 * age (years) þ 34.5 *
height (cm).
The FEV1 values obtained from these equations were
concordant with reference values for normal subjects
published by The Danish Lung Association.18 The spiro-
metric cut off values used in the GOLD classification was
applied for classifying disease severity:
GOLD 1: FEV1/FVC < 0.70 and FEV1%pred  80.
GOLD 2: FEV1/FVC < 0.70 and 50  FEV1%pred < 80.
GOLD 3: FEV1/FVC < 0.70 and 30  FEV1%pred < 50.
GOLD 4: FEV1/FVC < 0.70 and FEV1%pred < 30.
Subjects with normal spirometry were labelled as “no
COPD” regardless of lung symptoms.
Subjects 35 years of age or older with adequate lung
function data were included for analysis. Subjects younger
than 35 years of age were excluded because prevalence of
COPDwas thought to be negligible and uncertain. All subjects
who gave an affirmative answer to the question “do you have
asthma?” were considered asthmatics in accordance to
conventions fromprevious epidemiological studies.19 Because
many of those reporting to have asthma by definition fulfilled
the criteria of COPD the prevalence analyses were conducted
bothwith andwithout these subjects. In all other calculations
the asthmatics were excluded.
Smoking status was obtained from the questionnaire and
subjects were classified as smokers, ex-smokers or never-
smokers. Number of pack-years was calculated for ex-
smokers and smokers (1 pack-year Z 20 cigarettes per day
for one year).
At the physical examination weight and height were
recorded for every participant and BMI was calculated. In
each GOLD group mean BMI was calculated as well as the
percentage with BMI<21 kg/m2.
Co-morbidity was established from the questionnaire in
which the participants were asked about manifestations of
ischaemic heart disease, cerebrovascular disease, periph-
eral arterial disease, if they had diabetes, or if they had or
had ever had cancer. A previous history including myocar-
dial infarction, coronary artery by-pass grafting, percuta-
neous coronary intervention or chest pain on exertion was
taken as indicators of ischaemic heart disease. Stroke or
a history within 10 years of paralysis, difficulty controlling
movement of a limb or the face, blindness in one or both
eyes or disturbances of speech were taken as indicators of
cerebrovascular disease. Pain in one or both legs after
a period of walking, which could be relieved by stopping
was considered indicative of peripheral arterial disease.
Dyspnoeawas ascertained fromthequestionnaire. Subjects
were asked if they got breathless while walking fast or up hill,
whilewalkingwith individuals of their own age at normal pace,
if they occasionally had to stop to catch their breath while
walking at their own speed, if they got breathless while
dressingor if theywerebreathless at rest. Severity of dyspnoea
was graded accordingly from 0 to 5 where 0 was no dyspnoea
and 5 was dyspnoea at rest. Subjects answering affirmatively
to thequestion “do youoccasionally have to stopwhilewalking
at your own speed” was categorized as grade 3 which was
considered to be equivalent to a MRC (Medical Research
Council) dyspnoea score of 3.20
In the questionnaire the participants were asked if they
used medication for asthma or bronchitis on a daily or near
daily basis, but the type and dose were not reported.
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committee and informed consent was obtained from all
participants.
Statistics
The prevalence of COPD in various age groups is shown with
exact 95% confidence intervals computed from the F
distribution (based on the binomial cumulative distribution
function). The prevalence of COPD in various age groups
according to severity is also shown with approximate 95%
confidence intervals using Goodman’s simultaneous method
for multinomial proportions.21 The distribution of BMI was
approximately normal both in the total study population
and within the GOLD groups. For each GOLD group mean
BMI is shown with approximate 95% confidence intervals
derived from the mean value þ/ 1.96 SE. Student’s t-test
was used when comparing the mean BMI in the two genders.
The distribution of age and FEV1%pred was also approxi-
mately normal and the Student’s t-test was used corre-
spondingly. The distribution of pack-years was reversely
j-shaped and the ManneWhitney test was used when
comparing median pack-years between the genders. In all
other instances data was qualitative and the Chi-square
test was used to calculate p-values testing for equality
between genders and between subjects with and without
COPD. SPSS 12.0 was used for all calculations.22
Results
The study sample consisted of 5299 subjects, 3014 women
and 2285 men, of whom 368 reported to have asthma. The
mean age in the total study population was 62.6 years;
women on average being two years older than men (63.5
years vs. 61.4 years, p < 0.001).
The prevalence of COPD in various age groups is shown in
Table 1. Excluding asthmatics, the overall prevalence of
COPD was 17.4% in the study sample; increasing gradually
with age from 7.1% in the youngest age group to 26.9% among
subjects 80 years or older. COPD was more prevalent in men
than in women (19.4% vs. 15.8%, p < 0.001), particularly
among the elderly. When asthmatics were included in the
analyses the overall prevalence of COPD rose approximately
2% with no difference between the genders.
In Table 2 the prevalence is shown according to severity
of COPD using GOLD criteria. GOLD stages 3 and 4 are
combined due to low numbers; 6.2% had mild COPD (GOLD
1), 9.2% had moderate COPD (GOLD 2) and 2.0% had severe
or very severe COPD (GOLD 3 þ 4). COPD was more preva-
lent among men in all age groups and for all degrees of
severity except from moderate COPD among those between
65 and 79 years of age where the prevalence was equal
among the genders.
Table 3 shows prevalence and severity of COPD in
correlation to cumulated tobacco consumption. The prev-
alence of COPD increased from 7.9% among never-smokers
to 31.2% among individuals with a tobacco consumption of
30 pack-years or more. The severity of COPD followed the
exact same pattern rising gradually with increasing tobacco
consumption. The median cumulated tobacco consumption
was higher in men (27 pack-years vs. 18 pack-years,p < 0.001) but the correlation between smoking and COPD
was identical in the two genders. 51.1% of the subjects with
COPD still smoked with little difference between the GOLD
stages. At all stages of COPD, there were more male than
female smokers (55.3% vs. 47.7%, p < 0.005).
Mean BMI was slightly lower among subjects with COPD
compared to subjects without COPD (25.0 kg/m2 vs.
26.3 kg/m2, p < 0.001). After adjustment for age, gender,
pack-years and current smoking status the difference
between the two groups became bigger. Subjects with
COPD had a BMI of 1.9 kg/m2 (95% confidence interval
1.3e2.5 kg/m2) less than subjects without COPD. Women
had a mean BMI of 1.3 kg/m2 (0.5e2.1 kg/m2) less than
men. As shown in Table 4, there was only a small and
statistically non-significant difference in mean BMI between
the GOLD groups. Adjustment for age, gender, pack-years
and smoking status did not alter this. The fraction with
a BMI of less than 21 kg/m2 was higher among subjects with
COPD compared to subjects without COPD (12.6% vs. 8.1%,
p < 0.001), particularly driven by subjects with severe
disease. The fraction with BMI of less than 21 kg/m2 was
higher among women at all stages of COPD (12.4% vs. 4.2%,
p < 0.001) and among smokers (11.6% vs. 7.5% p < 0.001).
The prevalence of COPD among obese individuals with BMI
of 30 kg/m2 or more was lower than among the rest of the
population (11.2% vs. 18.6%, p < 0.005) due to a lower
occurrence of mild and moderate disease. In contrast mean
FEV1%pred was slightly lower among the obese compared to
the rest of the population (89.8% vs. 92.6%, p < 0.001). The
obese were a little older (64.9 years vs. 62.3 years,
p < 0.001) whereas the sex distribution was the same.
As shown in Table 4, dyspnoea increased with increasing
severity of COPD. Subjects with severe or very severe COPD
were on average moderately dyspnoeic corresponding to
a dyspnoea score of 2 whereas subjects with moderate
COPD on average had mild dyspnoea and a dyspnoea score
of 1. There was no difference in dyspnoea score among
subjects with no COPD and subjects with mild COPD.
Dyspnoea corresponding to a score of 3 or more became
increasingly frequent with increasing GOLD stage. Women
with COPD on average had slightly higher dyspnoea scores
than men and more often had dyspnoea scores of 3 or more
(18.9% vs. 14.4%, p Z 0.05).
Only 8.3% of subjects with COPD received some kind of
respiratory medication. As shown in Table 4 the treatment
prevalence increased step-wise with severity of COPD.
Among the subgroup with a dyspnoea score of 3 or more the
treatment prevalence was 19.3%. Among subjects without
asthma or COPD 1.8% were treated with respiratory medi-
cations. At all stages of COPD women were treated more
often than men (11.1% vs. 5.6%, p < 0.005).
As shown in Table 5, the prevalence of arteriosclerotic
disease (either manifest or symptoms indicating arterio-
sclerosis) was higher among subjects with COPD compared to
the rest of the population (ischaemic heart disease 13.3% vs.
9.5%, p < 0.001, cerebrovascular disease 23.0% vs. 17.8%,
p < 0.001, and peripheral arterial disease 22.9% vs. 16.0%,
p < 0.001) and tended to increase with severity of COPD.
There was a general male predominance among subjects
with ischaemic heart disease and apoplexia. There was
a stepwise increase in the prevalence of present or former
malignancies with increasing GOLD stage, women being
Table 1 Prevalence of COPD in different age groups.
Age groups 35e49 years 50e64 years 65e79 years 80 years
COPD prevalence 7.1% 14.2% 23.9% 26.9%
(Asthmatics excluded) [5.6e8.9]% [12.6e16.0]% [21.9e26.0]% [23.1e30.9]%
Total (72/1014) (241/1697) (403/1687) (137/510)
COPD prevalence 8.4% 17.1% 26.6% 31.7%
(Asthmatics excluded) [6.0e11.3]% [14.6e19.8]% [23.3e30.1]% [25.1e38.9]%
Men (39/466) (142/830) (175/658) (59/186)
COPD prevalence 6.0% 11.4% 22.2% 24.1%
(Asthmatics excluded) [4.2e8.4]% [9.4e13.7]% [19.7e24.8]% [19.5e29.1]%
Women (33/548) (99/867) (228/1029) (78/324)
COPD prevalence 8.4% 15.6% 26.4% 30.1%
(Asthmatics included) [6.8e10.2]% [14.0e17.3]% [24.4e28.5]% [26.3e34.1]%
Total (92/1093) (284/1822) (483/1830) (166/552)
COPD prevalence 10.6% 18.1% 29.2% 36.1%
(Asthmatics included) [8.0e13.6]% [15.6e20.8]% [25.8e32.7]% [29.5e43.2]%
Men (54/511) (157/869) (205/703) (73/202)
COPD prevalence 6.5% 13.3% 24.7% 26.6%
(Asthmatics included) [4.7e8.9]% [11.2e15.7]% [22.2e27.3]% [22.0e31.5]%
Women (38/582) (127/953) (278/1127) (93/350)
Values are shown for each gender separately and combined. Prevalence of COPD is shown in percentage, in different age groups, with
exact 95% confidential intervals in brackets, with and without asthmatics. In parenthesis the absolute number of subjects with COPD is
shown in relation to the total number of subjects within the age group.
Table 2 Severity of COPD in different age groups.
35e49 years 50e64 years 65e79 years 80 years
Women 3.5% 5.1% 5.7% 10.5%
GOLD 1 [2.0e6.0]% [3.5e7.3]% [4.2e7.8]% [7.0e15.5]%
(19/548) (44/867) (59/1029) (34/324)
Women 2.6% 5.4% 13.1% 11.4%
GOLD 2 [1.3e4.8]% [3.8e7.7]% [10.7e16.0]% [7.7e16.6]%
(14/548) (47/867) (135/1029) (37/324)
Women 0.0% 0.9% 3.3% 2.2%
GOLD 3þ4 [0.0e1.1]% [0.4e2.2]% [2.2e5.0]% [0.9e5.3]%
(0/548) (8/867) (34/1029) (7/324)
Men 3.6% 5.5% 8.8% 15.1%
GOLD 1 [2.0e6.5]% [3.9e7.9]% [6.4e12.0]% [9.6e22.7]%
(17/466) (46/830) (58/658) (28/186)
Men 4.5% 10.2% 12.9% 14.0%
GOLD 2 [2.6e7.6]% [7.9e13.2]% [10.0e16.5]% [8.8e21.5]%
(21/466) (85/830) (85/658) (26/186)
Men 0.2% 1.3% 4.9% 2.7%
GOLD 3þ4 [0.0e1.7]% [0.6e2.7]% [3.2e7.4]% [0.9e7.5]%
(1/466) (11/830) (32/658) (5/186)
Total 3.6% 5.3% 7.1% 12.0%
GOLD 1 [2.0e6.3]% [3.7e7.6]% [5.2e9.7]% [7.9e17.9]%
(36/1014) (90/1697) (117/1687) (62/510)
Total 3.5% 7.8% 13.0% 12.3%
GOLD 2 [2.0e6.2]% [5.9e10.4]% [10.4e16.2]% [8.1e18.2]%
(35/1014) (132/1697) (220/1687) (63/510)
Total 0.1% 1.1% 4.0% 2.3%
GOLD 3þ4 [0.0e1.4]% [0.5e2.4]% [2.6e6.1]% [0.9e6.0]%
(1/1014) (19/1697) (66/1687) (12/510)
Values are shown for each gender separately and combined. Prevalence of COPD is shown as percentage in different age groups with
approximate 95% confidence intervals in brackets, according to severity of disease, using the GOLD classification. In parenthesis the
number of subjects with COPD is shown in relation to the total number of subjects within the age group.
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Table 3 Prevalence of COPD according to tobacco exposure.
No COPD GOLD 1 GOLD 2 GOLD 3 þ 4
Never-smokers 92.1% 3.4% 3.8% 0.7%
[90.2e93.7]% [2.4e4.7]% [2.8e5.3]% [0.4e1.5]%
(1372/1490) (50/1490) (57/1490) (11/1490)
0e10 pack-years 90.2% 4.8% 4.3% 0.7%
[87.3e92.5]% [3.2e7.0]% [2.8e6.4]% [0.3e1.9]%
(739/819) (39/819) (35/819) (6/819)
10e30 pack-years 80.4% 7.9% 9.8% 2.0%
[77.4e83.1]% [6.2e10.0]% [7.8e12.1]% [1.2e3.2]%
(980/1219) (96/1219) (119/1219) (24/1219)
30 pack-years 68.8% 8.8% 18.2% 4.2%
[65.5e71.9]% [7.0e11.0]% [15.7e21.0]% [3.0e5.9]%
(892/1297) (114/1297) (236/1297) (55/1297)
Severity of COPD is shown in relation to total tobacco exposure. The percentage, with exact 95% confidence intervals in brackets, and
the total numbers, in parenthesis, are stated.
414 P. Fabricius et al.affected substantially more than men (12.8% vs. 6.4%,
p < 0.001). Diabetes was equally prevalent among individ-
uals with and without COPD (5.4% vs. 5.0%, p > 0.25) with
male predominance. Subjects with COPD were significantly
older and the average age increased gradually with severity
of COPD, from 61.4 years among subjects without COPD to
70.8 years among those in GOLD group 3 þ 4. As expected,
theprevalence of co-morbidity rose stepwisewith age. Itwas
consistently a little higher, regardless of age, in the subgroup
with COPD, rising from 23.2% among subjects aged 35e49
years to 63.9% among subjects older than 80 years. Among
subjects without COPD it rose from 19.4% to 62.2%.Table 4 BMI, dyspnoea and use of respiratory medication acco
No COPD GOLD 1
BMI in kg/m2
Total 26.3 24.4
[26.2e26.5] [23.0e24.
Men 26.9 25.1
[26.7e27.1] [24.6e25.
Women 25.9 23.7
[25.7e26.1] [23.2e24.
BMI < 21 kg/m2
Total 8.1% 12.1%
Men 3.8% 5.4%
Women 11.2% 18.6%
Mean dyspnoea score
Total 0.6 0.6
Men 0.5 0.6
Women 0.6 0.6
Dyspnoea score  3
Total 7.3% 7.5%
Men 6.2% 8.1%
Women 8.1% 7.1%
Respiratory medication
Total 1.8% 5.6%
Men 1.2% 3.4%
Women 2.3% 7.7%
Mean BMI with approximate 95% confidential intervals, prevalence of
with pulmonary medication is shown. All values are shown according
and combined.Discussion
We found an overall prevalence of COPD of 17.4% among
individuals 35 years of age or older participating in the 4th
exam of the Copenhagen City Heart Study. This is higher
than previously reported in this population.23 The COPD
prevalence follows the smoking prevalence but with
a considerable delay in time as it takes a prolonged period
of smoking to develop the disease. The smoking prevalence
in Denmark reached a peak around 1970 after which it has
declined slowly. However, it is primarily the light smokers
who have given up smoking and the total tobaccording to GOLD stage.
GOLD 2 GOLD 3 þ 4
25.4 25.7
7] [25.0e25.7] [24.6e26.8]
26.0 26.6
5] [25.5e26.5] [25.2e28.1]
24.8 24.8
2] [24.2e25.3] [23.3e26.4]
11.5% 19.2%
4.6% 14.3%
17.9% 24.0%
1.1 2.0
0.9 1.9
1.4 2.1
18.3% 37.3%
13.7% 36.7%
22.7% 38.0%
8.5% 16.3%
5.5% 12.2%
11.3% 20.4%
dyspnoea with a score of 2 or more and prevalence of treatment
to severity of COPD. Values are shown for each gender separately
Table 5 Prevalence of co-morbidities according to GOLD stage.
No COPD GOLD 1 GOLD 2 GOLD 3 þ 4
IHD 9.5% 10.5% 14.6% 16.3%
[8.7e10.5] [7.3e14.5] [11.5e18.2] [9.6e25.2]
CVD 17.8% 18.0% 25.4% 27.3%
[16.7e19.1] [13.9e22.8] [21.4e29.7] [18.8e37.1]
PAD 16.0% 20.8% 24.3% 24.5%
[14.9e17.1] [16.4e25.8] [20.4e28.5] [16.4e34.2]
Diabetes 5.0% 4.3% 6.2% 5.1%
[4.4e5.7] [2.3e7.2] [4.2e8.8] [1.7e11.4]
Cancer 9.6% 10.8% 12.1% 14.3%
[8.7e10.6] [7.6e14.9] [9.3e15.5] [8.0e22.8]
Prevalence in percentage with ischaemic heart disease (IHD), cerebral vascular disease (CVD), peripheral arterial disease (PAD), dia-
betes and cancer is shown according to GOLD stage. Approximate 95% confidence intervals are shown in brackets.
Prevalence of COPD in Copenhagen 415consumption has declined at a much slower rate.24 Also,
the life expectancy has gradually increased and the
proportion of elderly people has become larger. As the
COPD prevalence is markedly higher in the elderly pop-
ulation the total prevalence would tend to increase. A
combination of these factors could explain why the COPD
prevalence has increased, while at the same time the
smoking prevalence has decreased.
Estimates of COPD prevalence from studies in other
developed countries have ranged from 5 to 19% with the
majority being in the vicinity of 10%.5e16 Differences in
demographics, diagnostic tools, smoking patterns etc. are
the most likely explanation to the variance. The overall
prevalence in our study is among the highest reported so far
mainly due to the large fraction of women with COPD. The
prevalence among Danish women is lower than among the
men but extraordinarily high in an international
context.6,7,9,10,14 It reflects the sad fact that Danish women
were among the first to take up smoking and for many years
had the highest consumption in the world.24 The tobacco
consumption among Danish men does not differ from the
consumption in most European countries.24 Recent results
from an epidemiological trial in a rural part of Denmark,
where the tobacco consumption is smaller and the socio-
economic conditions are better than in Copenhagen, have
reported slightly lower prevalence rates, but a similar sex
distribution.25
In accordance with previous studies we found that both
prevalence and severity of COPD was closely linked to the
cumulated tobacco consumption. The finding that approx-
imately 50% of subjects with COPD still smoked was not
surprising but it highlights the need for a continuous effort
against smoking. It is noteworthy, though, that 13.8% of the
subjects with COPD had never smoked which corresponds to
a prevalence of COPD of 7.9% among never-smokers. Most
of these individuals were old and had mild to moderate
disease. Thus, COPD is primarily, but not exclusively,
associated with smoking. Not surprisingly, the prevalence
and the severity of COPD increased with age due to
a combination of larger tobacco consumption and the
cumulated physiological decline over time.
Our study is impeded by several methodological limita-
tions and the prevalence in the study sample may not
accurately reflect the “true” prevalence in the entirepopulation. International guidelines recommend post-
bronchodilator spirometry and reversibility testing before
a diagnosis is made and staging is carried out. In our study
the reversibility test was left out and some of the subjects
labelled with COPD may have had undisclosed asthma. A
small physiological improvement in the dynamic lung
volumes is often observed following bronchodilation and
some of the individuals with mild COPD may have had
normal lung function if they had been bronchodilated
before testing.26 Also, there is a physiological decline with
increasing age in the FEV1/FVC ratio. Using a fixed ratio of
0.7 results in a higher prevalence among the elderly
including some with no symptoms and no tobacco exposure.
According to the GOLD definition these subjects have COPD
but whether it is a “genuine” disorder or merely an insig-
nificant age related phenomenon is continously debated. In
this sense our estimate of mild to moderate COPD may be
too high. However, other factors may have lead to under-
estimation of the prevalence. The response rate at the
fourth survey was only 50% and our results may suffer from
non-response bias. The extent and importance of the bias is
difficult to determine as the local ethics comittee has not
allowed investigation of non-responders. A previous study
of non-responders in The Copenhagen City Heart Study
reported that non-responders on average were less healthy
than the responders27 whereas recent studies of non-
response bias in danish and swedish surveys suggest that
bias is relatively small and of less importance.28e30 Prob-
ably, the most severely affected and dyspnoeic COPD
patients did not show up for examination as it requires
some physical effort.
Within recent years it has been acknowledged that COPD
is not restricted to the lungs but is accompanied by
systemic manifestations with elevated inflammatory
markers, weight loss and muscle wasting.31,32 BMI is an
important prognostic factor and is included in the BODE-
index.17 Thus, our finding that mean BMI was reduced in
subjects with COPD was expected. We also expected to find
an inverse correlation between severity of disease and BMI.
Instead we found that BMI tended to rise with increasing
GOLD stage. Nevertheless, the fraction with BMI of less
than 21 was higher among subjects with severe COPD. Thus,
the BMI values among subjects with severe disease were
more extreme and the subjects were more likely to be
416 P. Fabricius et al.either underweight or obese. The physical inactivity
accompanying dyspnoea could explain the tendency
towards obesity and measures of fat free mass may more
accurately have reflected the systemic manifestations and
given a more uniform result. Alternatively, it may only be
a subset of subjects with severe disease who have systemic
manifestations. Previously, the association between BMI
and COPD has primarily been investigated in severely
affected patients committed frequently to the hospital. In
our cohort most subjects had mild to moderate COPD
whereas only a minor part had severe disease. The systemic
effects are likely to be of less importance at the early
stages of COPD but become more pronounced with disease
progression. The lower prevalence of COPD among obese
individuals may not be real since obesity is a known cause
of lung restriction, resulting in higher FEV1/FVC ratios. This
is supported by the slightly lower FEV1%pred among the
obese and undoubtedly some had reduced lung function of
mixed type with both airway restriction and obstruction.
As well as BMI, dyspnoea is a prognostic factor in COPD.33
In addition, dyspnoea is of importance when evaluating
patients for pulmonary rehabilitation. As expected we found
that dyspnoea became more frequent and worse with
increasingGOLD stage.However, it is noteworthy that a large
fraction of the individuals with COPD reported no or only very
little dyspnoea even at advanced stages of disease. It high-
lights the importance of performing spirometry in the pop-
ulation at risk. From our data it is possible to estimate the
need for pulmonary rehabilitation in the general population.
Subjects with disease in GOLD stage 2e4 with dyspnoea
corresponding to a score of 3 or more would be potential
candidates. Of the subjects with COPD 14% fulfill these
criteria which vastly exceeds the current capacity in
Copenhagen e and probably elsewhere.
Only aminority of the subjects with COPD received regular
pharmacological treatment. Even among subjectswith severe
dyspnoea and advanced disease the numbers treated with
respiratory medications were very low. Optimal pharmaco-
logical treatment has well documented effects on both the
course of disease and on symptoms34e36 and a strengthened
and continuous educational effort primarily targeted at the
general practitioners is called for to improve this situation.
Symptoms indicative of arteriosclerosis were present in
a large fraction of the study population. As the symptoms are
not specific to arteriosclerotic disease the true prevalence is
likely to be somewhat lower. As previously demonstrated we
found that subjects with COPD were older and more
burdened with cardiovascular disease and cancer than the
rest of the population.37,38 As smoking predisposes to
atherosclerosis and many types of cancer, this is not
surprising. The high frequency of curable breast cancer and
gynaecological cancers probably explain at least some of the
difference in cancer prevalence between the genders.
In conclusion, our study is among the largest studies in the
world on COPD prevalence. Subjects with COPD were thor-
oughly characterized with regard to age, severity of disease
and smoking status, which allows comparisons with other
studies. Further, as one of the first studies our subjects with
COPD are described by variables of prognostic importance
i.e, BMI, dyspnoea, co-morbidity and medication with
pulmonary medicine. Our study confirms that COPD is
a widespread and very common disease e perhaps more sothan what has previously been believed. It is closely corre-
lated to smoking and prevalence of COPD and disease
severity rise with increasing age. COPD is accompanied by an
increased occurrence of cardiovascular disease and cancer
and the patients are grossly under treated. Even with
continued decreasing tobacco consumption COPD will
remain a major health problem for many years to come.Conflict of interest
None.
References
1. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing
COPD a 25 year follow up study of the general population.
Thorax 2006;61:935e9.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic
obstructive pulmonary disease (COPD). Lancet 2004;364:613e20.
3. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis
and treatment of patients with COPD: a summary of the
ATS/ERS position paper. Eur Respir J 2004;23:932e46.
4. Murray CJ, Lopez AD. Alternative projections of mortality and
disability by cause 1990-2020: global Burden of Disease Study.
Lancet 1997;349:1498e504.
5. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the
diagnosis, management and prevention of chronic obstructive
pulmonary disease: GOLD Executive Summary. Am J Respir Crit
Care Med 2007;176:532e55.
6. Buist AS, Mcburnie MA, Vollmer WM, et al. International vari-
ation in the prevealence of COPD (The BOLD Study): a pop-
ulation-based prevalence study. Lancet 2007;370:741e50.
7. Lindberg A, Jonsson AC, Ro¨nmark E, Lundgren R, Larsson LG,
Lundba¨ck B. Prevalence of chronic obstructive pulmonary
disease according to BTS, ERS, GOLD and ATS criteria in rela-
tion to doctors’s diagnosis, symptoms, age, gender and
smoking habits. Respiration 2005;72:471e9.
8. Menezes MB, Perez-Padilla R, Jardim JRB, et al. Chronic
obstructive pulmonary disease in five Latin American cities
(the Platino study): a prevalence study. Lancet 2005;366:
1875e81.
9. Lindberg A, Bjerg-Backlund A, Ro¨nmark E, Larsson LG,
Lundba¨ck B. Prevalence and underdiagnosis of COPD by disease
severity and the attributable fraction of smoking Report from
the obstructive lung disease in Northern Sweden studies.
Respir Med 2006;100:264e72.
10. Murtaugh E, Heaney L, Gingles J, et al. The prevalence of
obstructive lung disease in a general population sample: the
NICECOPD study. Eur J Epidemiol 2005;20:443e53.
11. Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic
obstructive pulmonary disease in Korea: a population-based
spirometry survey. Am J Respir Crit Care Med 2005;172:842e7.
12. Cetinkaya F, Gulmez I, Aydin T, Ozturk Y, Ozesmi M, Demir R.
Prevalence of chronic bronchitis and associated risk factors in
a rural area of Kayseri, Central Anatolia, Turkey. Monaldi Arch
Chest Dis 2000;55:189e93.
13. De La Fuente Cid R, Gonzalez Barcala FJ, et al. COPD, a public
health problem. Rev Clin Esp 2006;206:442e3.
14. Menezes AM, Victora CG, Rigatto M. Prevalence and risk factors
for chronic bronchitis in Pelotas, RS, Brazil: a population-based
study. Thorax 1994;49:1217e21.
15. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the
Nippon COPD Epidemiology study. Respirology 2004 Nov;9(4):
458e65.
Prevalence of COPD in Copenhagen 41716. Mohangoo AD, van der Linden MW, Schellevis FG, Raat H.
Prevalence estimates of asthma or COPD from a health inter-
view survey and from general practitioner registration: what’s
the difference? Eur J Public Health 2006 Feb;16(1):101e5.
17. Celli BR, Cote CG, Marin JM, et al. The body-mass index,
airflow obstruction, dyspnea, and exercise capacity index in
chronic obstructive pulmonary disease. N Engl J Med 2004;350:
1005e12.
18. Spirometryea recommendation (in Danish). Copenhagen:
Danish Respiratory Society; 1986.
19. Tore´n K, Brisman J, Ja¨rvholm B. Asthma and asthma-like
symptoms in adults assessed by questionnaires. Chest 1993;
104:600e8.
20. Fletcher CM. Standardized questionnaire on respiratory symp-
toms: a statement prepared and approved by the MRC
Committee on the aetiology of chronic bronchitis (MRC
breathlessness score). BMJ 1960;2:241e3.
21. Goodman LA. On simultaneous confidence intervals for multi-
nomial proportions. Technometrics 1965;7:247e54.
22. Home page with specifications on SPSS 12.0, www.spss.com/
press/template_view.cfm?PR_IDZ614 [accessed 05.05.09].
23. Lange P, Parner J, Prescott E, Vestbo J. Chronic bronchitis in an
elderly population. Age Ageing 2003;32:636e42.
24. Home page from The Danish National Board of Health with
statistics regarding smoking, alcohol and drugs, www.sst.dk/
publ/publ2003/statistik2003.pdf [accessed 08.01.09].
25. Hansen JG, Pedersen L, Overvad K, Omland Ø, Jensen HK,
Sørensen HT. The prevalence of chronic obstructive pulmonary
disease among danes 45e84 years: population-based study. J
Chonic obstructive Pulm Dis 2008;5:347e52.
26. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications
of reversibility testing on prevalence and risk factors for
chronic obstructive disease: a community study. Thorax 2005;
60:842e7.
27. Lange P. Development and prognosis of chronic obstructive
pulmonary disease with special reference to the role of
tobacco smoking. Dan Med Bull 1992;39:30e48.28. Kjøller M, Thoning H. Characteristics of non-response in the
danish health interview surveys. Eur J Public Health
1987e1994;15(5):528e35.
29. Gundgaard J, Ekholm O, Hansen EH, Rasmussen NK. The effect
of non-response on estimates of health care utilisation: linking
health surveys and registers. Eur J Public Health, 18, 2,
189e194.
30. Ro¨nmark EP, Ekerljung L, Lo¨tvall J, Tore`n K, Ro¨nmark E,
Lundba¨ck B. Large sacle questionnaire survey on respiratory
health in Sweden: effects of late and non-response. Respir Med
2009 Dec;103(12):1807e15.
31. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease
as a systemic disease: an epidemiological perspective. Eur
Respir J 2003;22(Suppl. 46):2e4.
32. Wouters EFM, Creutzberg EC, Schols AMWJ. Systemic effects in
COPD. Chest 2002;121:127e30.
33. Oga T, Nishimura K, Tsukino M, Hajiro T, Mishima M. Dysp-
noea with activities of daily living versus peak dyspnoea
during exercise in male patients with COPD. Respir Med 2006
Jun;100(6):965e71.
34. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA,
Maslen TK. Randomised, double blind, placebo controlled
study of fluticasone propionate in patients with moderate to
severe chronic obstructive pulmonary disease: the ISOLDE
trial. BMJ 2000;320:1297e303.
35. Calverley PM, Anderson JA, Celli B, et alTORCH investigators.
Salmeterol and fluticasone propionate and survival in chronic
obstructive pulmonary disease. N Engl J Med 2007;356:775e89.
36. Rabe KF. Improving dyspnea in chronic obstructive pulmonary
disease: optimal treatment strategies. Proc Am Thorac Soc
2006;3:270e5.
37. Janson C, Gislason T, Suppli Ulrik C, et al. Characteristics of
hospitalised patients with COPD in the Nordic countries. Respir
Med 2006;100(Suppl. A):10e6.
38. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in
COPD: role of comorbidities. Eur Respir J 2006 Dec;28:
1245e57.
